Learning Hub Central

Filter by title, faculty, or specialty to find the course you're looking for.

SpecialtyLymphoma(63 courses)

All specialties

Lymphoma

63 courses

2026 MCM | Are We Making Progress in the Management of Low Grade (and Transformed) B-cell lymphomas

2026 MCM | What is New in the Management of T-cell Lymphomas?

2026 MCM | Management of Waldestrom in 2026

2025 Advances in Oncology | State of the Art in Non-Hodgkin Lymphoma

2025 SPS Seattle | Hodgkin Lymphoma Front Line Efficacy and Toxicity Considerations

2025 NOSCM | Follicular NHL: Novel Treatment Paradigms

2025 NOSCM | Hodgkin’s Disease: Novel Advances in Early and Advanced Stages

2025 NOSCM | The Complexity of Treatment Options for DLBCL: Novel Antibodies and CAR-T Cell Therapy

2025 NOSCM | Novel Advances in T-Cell NHL Therapies

2025 MLS Nashville | CLL/Lymphoma Updates

2024 NOSCM | Navigating Mantle Cell Lymphoma in the Era of Targeted Therapy

Updates in Lymphomas

2022 UCT | Modern Challenges and new options for B-cell NHL

2022 UCT | Update on T-cell Lymphomas

2024 PRIMO | Update on Novel Therapies for NHL

2024 NOSCM | CAR-T Cell Therapy in Lymphomas: 7-Years Later

2024 MCM | B-Cell NHL (Aggressive) - Relapsed (CAR T versus Bispecifics?)

2024 MCM | B-Cell NHL (Low-Grades)

Follicular Lymphoma and CLL Updates 2023

Follicular Lymphoma: Defining Best 1L and 2L Treatment in the Era of Personalized Medicine

Follicular, Marginal Zone and Mantle Cell NHL: Novel Advances

DLBCL & Hodgkin’s Disease

Lymphoma and CLL Update

2022 NOSCM | CAR T Cell Therapies in Lymphoid Malignancies: Here to Stay!

2024 MLS Nashville | CLL/Lymphoma Updates in 2024

Showing 25 of 63 courses

Contact Us

info@meccinc.com

(305) 663-1628

Powered By CMEGenius™

Privacy Policy Terms and Conditions Cancellation and Refund Policy AI Disclosure